spinal cord injury (sci) is a debilitating disease which leads to progressive functional damages. because of limited axonal regeneration in the central nervous system, there is no or little recovery expected in the patients. different cellular and molecular approaches were investigated in sci animal models. cellular transplantation of stem cells can potentially replace damaged tissue and provid...

BACKGROUND Mesenchymal stromal cells are multipotent cells considered to be of great promise for use in regenerative medicine. However, the cell dose may be a critical factor in many clinical conditions and the yield resulting from the ex vivo expansion of mesenchymal stromal cells derived from bone marrow may be insufficient. Thus, alternative sources of mesenchymal stromal cells need to be ex...

On November 16, 2017, the US FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. This risk-based framework includes a suite of guidance documents focusing on safety and effectiveness of these therapies, and reiterates FDA’s commitment to bring new effective therapies to patients as quickly and sa...

BACKGROUND Platelet-rich plasma (PRP) is increasingly used as a cell culture supplement, in order to reduce the contact of human cells with animal-derived products during in vitro expansion. The effect of supplementation changes on cell growth and protein production is not fully characterized. METHODS Human mesenchymal stromal cells from bone marrow, adipose tissue and Wharton's Jelly were is...

IBD: Inflammatory Bowel Disease ; UC: Ulcerative Colitis; CD: Crohn’s Diseases; TNF-α: Tumor Necrosis Factor α; IL12/23: Interleukin 12/23; IL-6R: Interleukin 6R; iRNA: information Ribonucleic acid; SC: Stem Cells; CT: Cell Therapy; MSC: Mesenchymal Stem Cells; HSC: Hematopoietic Stem Cells; 2,4,6-TNBA: 2,4,6-Trinitrobenzene Sulfonic Acid; SDF-1: Stromal Derived Factor-1; VEGF: Vasculoendotheli...

This review article reports on the new field of stem cell therapy and tissue engineering and its potential on the management of congenital heart disease. To date, stem cell therapy has mainly focused on treatment of ischemic heart disease and heart failure, with initial indication of safety and mild-to-moderate efficacy. Preclinical studies and initial clinical trials suggest that the approach ...

OBJECTIVE Although mesenchymal stem/stromal cells represent a promising therapeutic strategy for acute respiratory distress syndrome, clinical translation faces challenges, including scarcity of bone marrow donors, and reliance on bovine serum during mesenchymal stem/stromal cell proliferation. We wished to compare mesenchymal stem/stromal cells from human umbilical cord, grown in xeno-free con...